Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection

INTRODUCTION: Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection. METHODS: A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who r...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Infect Dis Ther
Auteurs principaux: Zhu, Li, Li, Hanbin, Chan, Phyllis, Eley, Timothy, Gandhi, Yash, Bifano, Marc, Osawa, Mayu, Ueno, Takayo, Hughes, Eric, AbuTarif, Malaz, Bertz, Richard, Garimella, Tushar
Format: Artigo
Langue:Inglês
Publié: Springer Healthcare 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986681/
https://ncbi.nlm.nih.gov/pubmed/29589331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-018-0197-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires